AOD-9604 Liver Function Impact: What the Evidence Actually Shows

What Is AOD-9604 and Why Does the Liver Matter?

AOD-9604 is a 16-amino-acid synthetic peptide corresponding to residues 176 through 191 of the human growth hormone molecule. Its primary studied application is adipose tissue reduction through lipolysis stimulation. The liver sits at the center of any discussion about peptide-based metabolic therapies because it is the primary site of GH-mediated IGF-1 synthesis, lipid oxidation, and first-pass peptide clearance.

The Structural Rationale for a Different Hepatic Profile

Full recombinant human growth hormone (rhGH, e.g., somatropin) binds the GH receptor on hepatocytes, driving IGF-1 production and altering hepatic glucose output. Prolonged supraphysiologic GH signaling is associated with hepatic insulin resistance, steatosis risk, and elevated transaminases in some patient populations. Recombinant GH safety data are catalogued in FDA prescribing labels accessible via the FDA drug database.

AOD-9604 lacks the binding domain required to activate the full GH receptor. Heffernan et al. Confirmed in animal models that the fragment retains fat-mobilizing activity while producing no detectable GH-receptor-mediated signaling, including no rise in circulating IGF-1. That mechanistic separation is the primary reason its hepatic risk profile is expected to differ from full GH. Heffernan et al., Endocrinology 2001

How the Liver Processes Peptide Drugs

Short peptides under roughly 20 amino acids are subject to proteolytic clearance in plasma and peripheral tissues rather than hepatic CYP450 metabolism. This means AOD-9604 does not compete for the cytochrome P450 pathways that generate most drug-drug interactions and transaminase elevations seen with small-molecule drugs. The kidneys and circulating peptidases handle most of the degradation load. Hepatic exposure is therefore more limited compared with orally administered small molecules that undergo first-pass extraction.

Animal Data: The Founding Evidence

The most frequently cited mechanistic study on AOD-9604 remains the 2001 Heffernan et al. Paper published in Endocrinology. Obese mice treated with AOD-9604 showed a statistically significant reduction in body fat without the metabolic distortions associated with full GH administration. Heffernan et al., Endocrinology 2001

What Heffernan et al. Measured

The Heffernan group specifically assessed IGF-1 levels, glucose tolerance, and adipose tissue mass in obese (ob/ob) and diet-induced obese mice. Full GH at equivalent doses elevated IGF-1 and worsened insulin sensitivity. AOD-9604 did neither. Hepatic outcomes were not the primary endpoint, but the absence of IGF-1 induction is directly relevant: hepatic IGF-1 synthesis is a GH-receptor-dependent process, and its absence implies the hepatocyte GH receptor was not substantially activated.

Beta-3 Adrenergic Pathway and Hepatic Lipid Flux

Subsequent animal work, including studies catalogued on PubMed examining beta-adrenergic lipolysis pathways, supports the view that AOD-9604 stimulates fat cell lipolysis through a beta-3 adrenergic-like mechanism rather than through hepatic signaling. Beta-3 adrenergic receptor pharmacology is reviewed in NCBI Bookshelf resources. Increased free fatty acid (FFA) release from adipose depots does present a secondary hepatic consideration: excess FFA delivery to the liver can contribute to hepatic lipid accumulation when rates exceed mitochondrial oxidative capacity. This risk appears dose-dependent and has not been observed at the doses studied in humans (500 mcg to 1 mg/day subcutaneous), though controlled human dose-escalation hepatic data remain sparse.

Human Trial Data and Liver Enzyme Findings

The METASCREEN program, a series of trials conducted in Australia and sponsored by Metabolic Pharmaceuticals, represents the most substantial human dataset for AOD-9604. The Phase IIb METASCREEN trial enrolled 300 overweight adults and ran for 24 weeks, examining multiple doses of oral AOD-9604 against placebo. The METASCREEN program background and trial registry details are referenced in NLM clinical trial documentation.

Transaminase Data From METASCREEN

The METASCREEN Phase IIb trial did not report statistically significant elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) in the AOD-9604 treatment arms relative to placebo at any of the tested doses. Alkaline phosphatase and total bilirubin likewise remained within reference ranges across the 24-week observation window. The trial used oral peptide delivery, which involves a different absorption kinetic than subcutaneous injection; however, the absence of hepatotoxic signal across both routes in the available data is noteworthy.

IGF-1 as a Hepatic Surrogate Marker

Because full GH exerts many of its hepatic effects through IGF-1 induction, the consistent finding that AOD-9604 does not raise IGF-1 serves as a functional surrogate for GH-receptor quiescence at the hepatocyte level. IGF-1 physiology and its hepatic regulation are detailed in endocrinology reference materials via NCBI. A 2004 open-label pharmacokinetic study of subcutaneous AOD-9604 (500 mcg dose) in healthy male volunteers confirmed no change in serum IGF-1 at 24 hours post-injection compared with baseline. Serum GH pulse amplitude was also unaffected, consistent with the peptide's lack of receptor agonism.

What "No Signal" Does Not Mean

An absence of transaminase elevation in a 300-person, 24-week trial is reassuring but not definitive for long-term safety. The trial was not powered to detect rare hepatic events occurring in fewer than 1 in 100 users. Chronic subcutaneous use beyond 24 weeks in the specific populations now using compounded AOD-9604 (including individuals with pre-existing NAFLD, metabolic syndrome, or concurrent GLP-1 agonist therapy) has not been formally studied in a controlled setting.

Mechanism-Based Hepatic Risk Assessment

Prescribers evaluating AOD-9604 for a patient should apply a structured hepatic risk stratification before initiating therapy. The following framework is used by the HealthRX medical team in clinical review:

Tier 1: Low Hepatic Risk

Patients meeting all of the following: BMI <35, no NAFLD or NASH diagnosis, ALT and AST within 1.5x the upper limit of normal (ULN) at baseline, no concurrent hepatotoxic medications (including high-dose statins, azole antifungals, or anabolic androgens), and no alcohol intake exceeding 14 units per week. For Tier 1 patients, baseline liver function tests (LFTs) and a 12-week follow-up panel are considered adequate monitoring under current 503A compounding protocols.

Tier 2: Moderate Hepatic Risk

Patients with one or more of the following: documented NAFLD with or without fibrosis stage F0-F2 on imaging, ALT between 1.5x and 3x ULN at baseline, BMI >35, or concurrent use of anabolic peptides (e.g., BPC-157, TB-500). Tier 2 patients require baseline LFTs, a 6-week recheck, and a 12-week panel. If ALT rises above 3x ULN at any recheck, AOD-9604 should be paused and a hepatologist consulted.

Tier 3: High Hepatic Risk / Defer or Contraindicate

Active hepatitis B or C, cirrhosis at any Child-Pugh stage, ALT above 3x ULN at baseline, or concurrent anabolic androgen use. AOD-9604 should not be initiated in Tier 3 patients outside a formal research protocol with dedicated hepatic monitoring. Guidance on hepatotoxicity grading thresholds is published by the FDA Drug-Induced Liver Injury Network.

Comparison With Full Growth Hormone: Why the Distinction Matters

Full rhGH therapy carries a recognized hepatic risk profile distinct from the peptide fragment. Somatropin at supraphysiologic doses has been associated with transient transaminase elevations in GH-deficient adults during the titration phase, an effect attributed to rapid restoration of hepatic metabolic activity and IGF-1 induction. The FDA prescribing information for somatropin products documents this finding.

AOD-9604 does not replicate this pattern because it does not drive hepatic IGF-1 synthesis. The endocrine society's clinical practice guideline on adult GH deficiency (2011, updated 2019) identifies IGF-1 normalization as a target of GH replacement and simultaneously as a marker of hepatic GH-receptor engagement. Endocrine Society GH deficiency guidelines are available via the Endocrine Society website. The absence of IGF-1 elevation with AOD-9604 is therefore both a pharmacodynamic characteristic and an indirect hepatic safety signal.

Anabolic Androgen Co-Administration: A Confounding Risk

A meaningful proportion of individuals using compounded AOD-9604 in real-world 503A settings also use testosterone replacement therapy (TRT) or anabolic peptides. Testosterone at TRT doses rarely elevates transaminases significantly when administered via injection rather than oral 17-alpha-alkylated forms. However, the combination of any lipolytic agent with high-dose androgens, which may alter hepatic lipid metabolism, requires careful interpretation of LFT results during AOD-9604 therapy. A rise in ALT in this context should not be attributed to AOD-9604 without ruling out androgen-related cholestasis. Androgen-related hepatic effects are reviewed in a PubMed-indexed systematic review.

Monitoring Protocol: Specific Parameters and Timing

Standard hepatic monitoring for AOD-9604 in a compounding pharmacy (503A) context should include the following specific tests and intervals.

Baseline Panel (Before First Dose)

ALT, AST, alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin, albumin, and a complete metabolic panel. A fasting lipid panel is also warranted because lipolysis acceleration may transiently raise circulating free fatty acids and, in rare cases, triglycerides. Fasting lipid panel interpretation guidelines are published by the American Heart Association.

6-Week Recheck (Tier 2 and 3 Only)

Repeat ALT, AST, GGT, and total bilirubin. If all values remain below 1.5x ULN, continue at current dose.

12-Week Panel (All Patients)

Full LFT panel including ALP, albumin, and bilirubin fractionation. Add serum IGF-1 as a pharmacodynamic check. An IGF-1 rise above the age- and sex-adjusted reference range at this timepoint should prompt reassessment of the peptide source and a review for undisclosed GH secretagogue co-administration, not necessarily an immediate discontinuation.

Action Thresholds

• ALT or AST 1.5x to 3x ULN: increase monitoring to every 4 weeks, hold dose escalation.
• ALT or AST above 3x ULN on two consecutive measurements: pause AOD-9604, pursue liver ultrasound and hepatology referral.
• Any elevation with concurrent jaundice or coagulopathy (INR above 1.5): immediate discontinuation and emergency hepatology evaluation. This combination meets the Hy's Law criterion for serious drug-induced liver injury. The FDA Hy's Law guidance is available on the FDA website.

Current Regulatory and Compounding Context

AOD-9604 is not FDA-approved as a finished drug product. It is available in the United States through 503A compounding pharmacies on a patient-specific prescription basis. The FDA issued a memorandum in 2015 indicating that AOD-9604 does not meet the criteria for inclusion on the 503A Bulks List under section 503A of the FD&C Act, which introduced a period of legal uncertainty for compounders. The FDA 503A bulk drug substance framework is described on the FDA website.

Some 503A pharmacies continue to compound AOD-9604 under a clinical-need argument, but prescribers should verify the legal and accreditation status of the compounding pharmacy before ordering. PCAB-accredited pharmacies adhering to USP 795 and 797 standards provide the most reliable product quality and potency verification. Potency variability in compounded peptides is itself a hepatic safety consideration: a preparation delivering 3x the labeled dose would present proportionally higher FFA flux to the liver.

The GRAS Safety Review: What It Covers

Metabolic Pharmaceuticals submitted AOD-9604 for Generally Recognized as Safe (GRAS) status in the context of a food ingredient application, and the peptide received a no-objection letter from the FDA in 2014 for oral use as a food additive. FDA GRAS notification details are searchable via the FDA GRAS database. The GRAS designation covers oral ingestion at much lower doses than those used therapeutically and does not extend to injectable formulations. Prescribers should not interpret the GRAS designation as a comprehensive injectable safety endorsement.

What Clinicians Are Watching in 2025

The most relevant clinical development for AOD-9604 hepatic safety in 2025 is the increasing use of the peptide alongside GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). GLP-1 agonists have their own hepatic data: SUSTAIN-6 (N=3,297) showed no significant hepatic signal with semaglutide 0.5 mg and 1 mg weekly over 104 weeks. SUSTAIN-6 primary results are indexed on PubMed. Emerging real-world data also show that liraglutide and semaglutide may reduce hepatic steatosis in NAFLD, a finding confirmed in the LEAN trial (liraglutide 1.8 mg, N=52, 48 weeks) published in The Lancet. LEAN trial Lancet publication.

Whether AOD-9604 combined with a GLP-1 agonist produces additive lipolytic flux sufficient to worsen hepatic FFA loading in susceptible patients has not been formally studied. This is a clinical gap that the HealthRX medical team tracks as a priority monitoring question for patients on both agents.